Cargando…

Association of CYP2C19 Polymorphism With Proton Pump Inhibitors Effectiveness and With Fractures in Real‐Life: Retrospective Cohort Study

Symptom refractoriness of patients treated with proton pump inhibitors (PPIs) might be explained by polymorphism in CYP2C19. This is a retrospective cohort study in which we used the computerized database of Clalit Health Services to compose a cohort from cancer case‐control studies’ participants th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gronich, Naomi, lavi, Idit, Lejbkowicz, Flavio, Pinchev, Mila, Rennert, Gad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9311419/ https://www.ncbi.nlm.nih.gov/pubmed/35124810 http://dx.doi.org/10.1002/cpt.2552

Ejemplares similares

Development of APE1 enzymatic DNA repair assays: low APE1 activity is associated with increase lung cancer risk
por: Sevilya, Ziv, et al.
Publicado: (2015)

Association of atrial fibrillation and cancer: Analysis from two large population-based case-control studies
por: Saliba, Walid, et al.
Publicado: (2018)

The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism
por: Gao, Nanyong, et al.
Publicado: (2022)

The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors
por: Sychev, DA, et al.
Publicado: (2015)

Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole
por: Mafuru, Magesa, et al.
Publicado: (2021)

Tyrosine kinase-targeting drugs-associated heart failure
por: Gronich, N, et al.
Publicado: (2017)

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
por: El Rouby, Nihal, et al.
Publicado: (2018)

Polymorphisms in Alcohol Metabolism Genes ADH1B and ALDH2, Alcohol Consumption and Colorectal Cancer
por: Crous-Bou, Marta, et al.
Publicado: (2013)

Long term follow-up of EGFR mutated NSCLC cases
por: Rennert, Gad, et al.
Publicado: (2020)

Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter Pylori
por: Lin, Yun-An, et al.
Publicado: (2017)

Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors
por: Deshpande, Neha, et al.
Publicado: (2016)

CYP2C19 genotypes and osteoporotic fractures in long‐term users of proton pump inhibitors: A hospital‐based study
por: Liao, Yi‐Ju, et al.
Publicado: (2023)

Proton-Pump Inhibitors and Fragility Fractures in Vulnerable Older Patients
por: Zirk-Sadowski, Jan, et al.
Publicado: (2017)

Proton Pumps: Molecular Mechanisms, Inhibitors and Activators of Proton Pumping
por: Siletsky, Sergey A.
Publicado: (2023)

Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study
por: Shibli, Rana, et al.
Publicado: (2021)

N-Methylpurine DNA Glycosylase and OGG1 DNA Repair Activities: Opposite Associations With Lung Cancer Risk
por: Leitner-Dagan, Yael, et al.
Publicado: (2012)

Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: An updated meta-analysis
por: Zhao, Xianghong, et al.
Publicado: (2022)

Proton Pump Inhibitors and Gastritis
por: Suzuki, Masayuki, et al.
Publicado: (2008)

Proton pump inhibitors and gastroenteritis
por: Hassing, Robert-Jan, et al.
Publicado: (2016)

Deprescribing proton pump inhibitors
por: Teh, Kim Jun Kevin, et al.
Publicado: (2023)

Proton Pump Inhibitors and Fractures in Adults: A Critical Appraisal and Review of the Literature
por: Briganti, Silvia Irina, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)

Proton pump inhibitors and hypomagnesemia monitoring
por: Lemon, Thomas I
Publicado: (2013)

Use and overuse of proton pump inhibitors
por: Staiano, Annamaria, et al.
Publicado: (2015)

Symptomatic hypomagnesemia and proton pump inhibitors
por: Tin, Sim Sai, et al.
Publicado: (2014)

Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis
por: Nassar, Yousef, et al.
Publicado: (2018)

Proton Pump Inhibitors and Fracture Risk: A Review of Current Evidence and Mechanisms Involved
por: Thong, Benjamin Ka Seng, et al.
Publicado: (2019)

Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes
por: Chou, Ya-Shuan, et al.
Publicado: (2020)

CYP2C19 and STAT6 Variants Influence the Outcome of Proton Pump Inhibitor Therapy in Pediatric Eosinophilic Esophagitis
por: Mougey, Edward B., et al.
Publicado: (2019)

Risk of Pyogenic Liver Abscess in Proton Pump Inhibitor Users: New Inventory of Proton Pump Inhibitor Induced Complications?
por: Bang, Ki Bae
Publicado: (2021)

Management of laryngopharyngeal reflux with proton pump inhibitors
por: Reimer, Christina, et al.
Publicado: (2008)

Proton Pump Inhibitor Induced Depigmentation in Vitiligo
por: Holla, Anantha Prasad, et al.
Publicado: (2011)

Proton pump inhibitor-induced hypomagnesemic hypoparathyroidism
por: Swaminathan, Krishnan
Publicado: (2015)

Proton pump inhibitors: A balanced view
por: Ramakrishna, B.S.
Publicado: (2015)

Proton Pump Inhibitors: The Culprit for Barrett’s Esophagus?
por: Alsalahi, Omran, et al.
Publicado: (2015)

Proton pump inhibitors affect the gut microbiome
por: Imhann, Floris, et al.
Publicado: (2016)

Is hypomagnesemia associated with using proton pump inhibitors?
por: Yi, Joo-Hark, et al.
Publicado: (2016)

Proton Pump Inhibitor-associated Mucosal Change
por: Kato, Mototsugu, et al.
Publicado: (2017)

Proton pump inhibitors induce hemolytic anemia
por: Al-Nasser, Asayil Nasser, et al.
Publicado: (2019)

When is proton pump inhibitor use appropriate?
por: Yadlapati, Rena, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l5555c85jgs6aho8r9nm55rpm2